Government Plan to Expand Medicare HIV Coverage Is Dropped

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

WASHINGTON-The Clinton administration has decided not to extend Medicaid coverage to all low-income people infected with HIV. Currently, HIV-positive patients who have developed AIDS can receive Medicaid benefits even if they are not poor enough to qualify under normal Medicaid guidelines.

WASHINGTON—The Clinton administration has decided not to extend Medicaid coverage to all low-income people infected with HIV. Currently, HIV-positive patients who have developed AIDS can receive Medicaid benefits even if they are not poor enough to qualify under normal Medicaid guidelines.

The administration had speculated that extending the AIDS exception would be cost effective by allowing HIV-positive patients to receive the newer HIV drug combinations that may prevent progression to AIDS.

However, Victor Zonana, a spokesman for the Department of Health and Human Services, said that none of the proposals for the expansion analyzed by the government yielded a “revenue-neutral” plan, that is, one that would not increase spending over a 5-year period.

Although the administration has declined to make the change nationwide, individual states have the option of developing and submitting their own proposals for such a change, if they can be shown not to increase costs. According to Mr. Zonana, at least three states—Maine, Massachusetts, and Florida—have expressed an interest in doing so.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.